GREY:IPHAF - Post by User
Post by
biodelatechon Oct 12, 2005 6:54am
411 Views
Post# 9688343
Let´s face it
Let´s face it247 has done extremely well in clinical trials so far, both in terms of side-effects and efficacy. It´s a godsend for patients.
so why aren´t those top-notch managers reasonable enough to lower their salaries in light of the limited financial resourscs.
they will strike it superrich anyway when 247 hits the market.
instead the common shareholder will have to endure further dilutive share offerings owing to the excessive greed by our top notch managers who can´t seem to hold back their spending sprees or whatever until 247 starts raking in the money for them and us common shareholders.